Condition
    Moderate Evidence
    Effectiveness 3/5

    Omega-3 Fatty Acids for Non-Alcoholic Fatty Liver Disease

    Omega-3s reduce liver fat and triglycerides in NAFLD trials and are the best-supported supplement for this condition — but they work as an adjunct to weight loss, which remains the only intervention proven to reverse the disease.

    Overview

    Omega-3s are the most consistently supported supplement for non-alcoholic fatty liver disease, and importantly the effect is on liver fat itself rather than only on blood markers.
    Meta-analyses of randomised trials report reduced hepatic fat measured by ultrasound, MRI or spectroscopy, alongside falls in triglycerides and often modest reductions in ALT. Doses of roughly 2 to 4 g of combined EPA and DHA over six months or more produce the clearest signal. The reduction is meaningful but partial. Omega-3s do not reliably improve fibrosis or resolve steatohepatitis, and they do not substitute for the intervention with the largest effect - weight loss of around 7 to 10 percent, which can reverse steatosis outright.

    No studies are currently linked to this pairing

    This page reflects published clinical literature and conventional dosing rather than trial data attached to this concern in our library.

    How It Works

    Hepatic steatosis reflects an imbalance between fat delivery and synthesis on one side and oxidation and export on the other. EPA and DHA act on both. As ligands for PPAR-alpha they upregulate fatty acid beta-oxidation, and by suppressing SREBP-1c they reduce de novo lipogenesis - the two dominant levers on liver fat content.
    They also lower hepatic VLDL triglyceride production, improve membrane fluidity and insulin signalling, and generate specialised pro-resolving mediators such as resolvins and protectins that dampen the inflammatory component. What they do not do is address the fibrotic remodelling that defines advanced disease. Once stellate cell activation and collagen deposition are established, changing lipid flux does not undo them - which explains the gap between good steatosis data and weak fibrosis data.

    Dosing & Protocol

    Effective doses in NAFLD are considerably higher than general cardiovascular dosing.
    ContextDoseFormTiming
    Common trial range2-4 g combined EPA + DHA dailyTriglyceride-form fish oil or ethyl esterWith a fat-containing meal
    Lower practical dose1-2 g EPA + DHA dailyFish oilWith food
    Label cautionRead EPA + DHA, not total fish oil-A 1,000 mg capsule often supplies only 300 mg EPA + DHA
    Assessment window6-12 months-Liver fat change is slow; repeat imaging or ALT

    Weight loss remains the primary treatment

    Losing 7-10 percent of body weight reduces liver fat far more than any supplement, and is the only approach shown to improve steatohepatitis and fibrosis. Omega-3 is an adjunct.

    Evidence

    There are currently no studies linked to this pairing in our library, so no study list is shown.
    Several meta-analyses of randomised controlled trials in NAFLD report significant reductions in hepatic fat content and serum triglycerides with omega-3 supplementation, with smaller and less consistent improvements in ALT and AST. Imaging-based endpoints strengthen confidence, since they measure the disease process rather than a proxy. Limitations matter here. Trials differ widely in dose, EPA to DHA ratio, formulation and duration; many are small; histological endpoints are rare because biopsy is invasive; and the large WELCOME trial found reduced liver fat without improvement in fibrosis. Treat the evidence as good for steatosis, absent for fibrosis.

    Liver fat yes, fibrosis no

    Consistent evidence for reducing hepatic fat and triglycerides. No reliable evidence for improving fibrosis or resolving NASH.

    Safety

    Omega-3s are well tolerated at these doses. Fishy aftertaste, reflux and loose stools are the usual complaints, reduced by taking capsules with food or freezing them. Quality matters: choose products tested for oxidation and heavy metals, since rancid oil is pro-oxidant.

    Fatty liver needs monitoring, not self-management

    NAFLD can progress to steatohepatitis, fibrosis and cirrhosis silently. Persistent abnormal liver enzymes require medical assessment, including exclusion of viral hepatitis, alcohol-related disease and autoimmune causes.

    At 3 to 4 g daily there is a mild antiplatelet effect, relevant if you take anticoagulants or are approaching surgery. High-dose EPA formulations have also been associated with a small increase in atrial fibrillation risk in cardiovascular trials, which is worth discussing if you have a history of arrhythmia.

    Interactions & Conflicts

    The relevant interactions concern bleeding risk and metabolic co-treatment.
    Interacts withSeverityMechanismAction
    Warfarin and DOACs
    moderate
    		Additive antiplatelet effect at 3 g or more dailyDiscuss with your prescriber before high-dose use
    Antiplatelet drugs
    moderate
    		Additive bleeding riskUse lower doses or medical supervision
    Planned surgery
    moderate
    		Bleeding riskDiscuss stopping in advance with your surgeon
    Alcohol
    high
    		Alcohol drives hepatic steatosis and undermines any benefitMinimise or avoid alcohol in fatty liver disease
    Vitamin E or pioglitazone
    low
    		Used in NASH management; no adverse interaction expectedCoordinate through your hepatology team

    References

    No studies are currently linked to this pairing, so no reference list is available. This section will populate as evidence is added to the library.

    Frequently Asked Questions

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.